RDH12 — retinol dehydrogenase 12

The RDH12 gene provides instructions for making an important enzyme called retinol dehydrogenase 12. This enzyme is found in the retina, the light-sensitive tissue at the back of the eye, specifically within the light-detecting cells called photoreceptors. When light enters the eye, it triggers a chemical reaction involving Vitamin A that allows us to see. This process produces waste products that can be toxic to the cells. The RDH12 enzyme acts like a cellular cleaner, helping to break down and clear away these toxic byproducts, protecting the photoreceptor cells from damage caused by light exposure. When the RDH12 gene is mutated, the enzyme doesn't work properly or isn't produced at all. Without this protective cleaning process, toxic substances build up inside the photoreceptor cells. Over time, this buildup causes the cells to become stressed and eventually die. Because these cells are essential for vision, their loss leads to progressive vision problems. For patients, this usually means severe vision loss starting in early childhood, a condition often diagnosed as Leber Congenital Amaurosis (LCA) or early-onset severe retinal dystrophy. Symptoms include poor night vision, loss of peripheral (side) vision, and eventually loss of central vision, often leading to legal blindness by early adulthood. RDH12-related retinal disease is most commonly inherited in an autosomal recessive pattern. This means a person must inherit two mutated copies of the gene (one from each parent) to develop the disease. The parents, who each carry one mutated copy, typically do not have any vision problems themselves. In rare cases, a different type of mutation in the RDH12 gene can cause an autosomal dominant form of the disease, where inheriting just one mutated copy is enough to cause vision loss, though this form usually starts later in life and is less severe. Understanding the specific genetic mutation helps families know what to expect and is important for future family planning.

Gene description: Encodes an enzyme involved in the visual cycle, specifically catalyzing the reduction of all-trans-retinal to all-trans-retinol.

Patient and family guide: The RDH12 gene provides instructions for making an important enzyme called retinol dehydrogenase 12. This enzyme is found in the retina, the light-sensitive tissue at the back of the eye, specifically within the light-detecting cells called photoreceptors. When light enters the eye, it triggers a chemical reaction involving Vitamin A that allows us to see. This process produces waste products that can be toxic to the cells. The RDH12 enzyme acts like a cellular cleaner, helping to break down and clear away these toxic byproducts, protecting the photoreceptor cells from damage caused by light exposure. When the RDH12 gene is mutated, the enzyme doesn't work properly or isn't produced at all. Without this protective cleaning process, toxic substances build up inside the photoreceptor cells. Over time, this buildup causes the cells to become stressed and eventually die. Because these cells are essential for vision, their loss leads to progressive vision problems. For patients, this usually means severe vision loss starting in early childhood, a condition often diagnosed as Leber Congenital Amaurosis (LCA) or early-onset severe retinal dystrophy. Symptoms include poor night vision, loss of peripheral (side) vision, and eventually loss of central vision, often leading to legal blindness by early adulthood. RDH12-related retinal disease is most commonly inherited in an autosomal recessive pattern. This means a person must inherit two mutated copies of the gene (one from each parent) to develop the disease. The parents, who each carry one mutated copy, typically do not have any vision problems themselves. In rare cases, a different type of mutation in the RDH12 gene can cause an autosomal dominant form of the disease, where inheriting just one mutated copy is enough to cause vision loss, though this form usually starts later in life and is less severe. Understanding the specific genetic mutation helps families know what to expect and is important for future family planning.

Gene function: RDH12 is a key enzyme in the visual cycle, responsible for converting all-trans-retinal to all-trans-retinol in photoreceptor cells. This step is crucial for regenerating 11-cis-retinal, the chromophore of rhodopsin and cone opsins, which is necessary for light perception. Dysfunction of RDH12 leads to an accumulation of toxic retinoids and impaired chromophore regeneration, causing severe and early-onset retinal degeneration.

Protein structure: The RDH12 gene encodes a protein of 316 amino acids with a molecular weight of approximately 35 kDa. It belongs to the short-chain dehydrogenase/reductase (SDR) superfamily. The protein structure includes a cofactor binding site that interacts primarily with NADPH (and to a lesser extent NADH), a catalytic domain essential for its enzymatic activity, and an amino-terminal motif consisting of beta-strands and alpha-helices. While the exact tertiary structure of RDH12 has not been fully crystallized, modeling suggests it forms a globular structure typical of SDR enzymes. The protein localizes to the inner segments of photoreceptors. Unlike some other visual cycle proteins, RDH12 does not typically assemble into large multi-protein complexes but functions as a monomer or homodimer to exert its dual-specificity reductase activity on retinoids and other aldehydes.

Molecular function: Retinol dehydrogenase 12 (RDH12) is an enzyme belonging to the short-chain dehydrogenase/reductase (SDR) superfamily. It functions primarily as an NADPH-dependent retinal reductase. Its main biochemical activity is the reduction of all-trans-retinal and 11-cis-retinal to their corresponding retinols (all-trans-retinol and 11-cis-retinol). While RDH8 in the outer segments handles the bulk of all-trans-retinal reduction in the visual cycle, RDH12 is localized to the inner segments of photoreceptors. The primary physiological role of RDH12 is believed to be protective rather than purely central to the visual cycle. It is thought to clear excessive all-trans-retinal that escapes the outer segments and migrates to the inner segments. More importantly, RDH12 plays a crucial role in detoxifying toxic aldehydes produced by light-exposure-mediated lipid peroxidation, such as 4-hydroxynonenal (4-HNE). By reducing these toxic aldehydes and excessive retinal, RDH12 protects photoreceptors from oxidative stress and endoplasmic reticulum (ER) stress. When RDH12 is mutated and non-functional, the accumulation of these toxic byproducts leads to increased cellular sensitivity to light-induced oxidative injury, stress signaling, and ultimately, photoreceptor apoptosis. Thus, RDH12 is essential for maintaining retinoid homeostasis and protecting photoreceptor cells from light-induced damage.

Expression pattern: The RDH12 gene is highly expressed in the inner segments of photoreceptor cells in the retina. It is present in both rod and cone photoreceptors. The enzyme localizes specifically to the inner segments, which distinguishes it from other visual cycle enzymes like RDH8 that are found in the outer segments. RDH12 expression is crucial for the proper functioning and survival of photoreceptors. While its primary and most significant expression is in the retina, some studies have suggested minor expression in other tissues, but its critical physiological role is overwhelmingly confined to the ocular tissues, specifically the photoreceptor inner segments, where it helps manage the toxic byproducts of the visual cycle and light exposure.

Mutation spectrum: The mutation spectrum of the RDH12 gene is diverse, with over 116 variants reported in databases like ClinVar. The majority of these are missense mutations (approximately 68%), followed by nonsense mutations (12%), frameshifts (8%), splice-site variants (6%), and variants in untranslated regions. Copy number variations, including insertions, deletions, and duplications, have also been identified. Pathogenic variants are distributed throughout the gene, affecting critical regions such as the catalytic domain and cofactor binding sites. Common homozygous genotypes include p.Thr49Met, p.Ala126Val, p.Tyr226Cys, and p.Cys201Arg, with some founder effects observed in specific populations (e.g., p.Ala126Val in the Israeli population). While most mutations cause autosomal recessive disease through a loss-of-function mechanism, a distinct subset of frameshift mutations in the C-terminal region causes autosomal dominant retinitis pigmentosa, likely through a toxic gain-of-function mechanism.

Pathogenic variants: 1. p.Cys201Arg (c.601T>C) - A common missense mutation frequently found in patients of Indian descent, associated with severe autosomal recessive early-onset severe retinal dystrophy (EOSRD)/LCA. 2. p.Ala126Val (c.377C>T) - A prevalent missense variant, particularly noted as a founder mutation in the Israeli population, causing severe autosomal recessive EOSRD/LCA. 3. p.Thr49Met (c.146C>T) - A missense variant that has been associated with a relatively milder phenotype compared to other recessive mutations, sometimes presenting as later-onset retinal dystrophy. 4. p.Leu99Ile (c.295C>A) - Another missense variant associated with a milder clinical presentation, often found in homozygous or compound heterozygous states in patients with less severe disease progression. 5. c.778delG (p.Val260* or frameshift) - A specific heterozygous frameshift mutation in the C-terminal region that causes autosomal dominant retinitis pigmentosa, likely through a toxic gain-of-function mechanism.

Clinical significance: Mutations in the RDH12 gene are primarily associated with early-onset severe retinal dystrophy (EOSRD) and Leber Congenital Amaurosis (LCA), which are among the most severe forms of inherited retinal diseases. Patients typically present with severe visual impairment in infancy or early childhood, often progressing to legal blindness before the third decade of life. Clinical features include early progressive macular degeneration, which can appear as a petal-shaped, coloboma-like macular atrophy with a variegated watercolor-like pattern. Other common signs are early peripheral retinal pigment epithelium (RPE) atrophy with bone spicule pigmentation, peripapillary sparing, and markedly reduced scotopic and photopic electroretinogram (ERG) responses. In addition to EOSRD/LCA, RDH12 mutations can also cause other phenotypes such as retinitis pigmentosa (RP), cone-rod dystrophy (CORD), and macular dystrophy. While the majority of cases are inherited in an autosomal recessive manner and present with severe, early-onset disease, some heterozygous mutations have been linked to an autosomal dominant form of retinitis pigmentosa. This dominant form typically has a later onset and a relatively milder disease course compared to the recessive forms. Systemic features are generally not associated with RDH12 mutations, as the disease is typically confined to the eyes.

Inheritance: Autosomal Recessive

Chromosomal location: 14q24.1

Genotype-phenotype correlations: Genotype-phenotype correlations in RDH12-associated retinopathy show significant variability. The most common presentation, caused by biallelic (homozygous or compound heterozygous) loss-of-function mutations, is early-onset severe retinal dystrophy (EOSRD) or Leber Congenital Amaurosis (LCA). These patients experience severe, early-onset visual impairment and rapid progression. However, certain missense variants, such as p.Thr49Met and p.Leu99Ile, have been associated with milder phenotypes, including later-onset retinitis pigmentosa or macular dystrophy, suggesting that these alleles may retain some residual enzymatic activity. Interestingly, specific heterozygous frameshift mutations in the C-terminal region of the RDH12 protein (e.g., c.763delG, c.778delG, and c.759delC) cause an autosomal dominant form of retinitis pigmentosa. This dominant phenotype is generally milder and has a later onset than the recessive forms. It is hypothesized that these specific frameshift mutations result in a mutant protein that exerts a toxic gain-of-function or dominant-negative effect, leading to photoreceptor degeneration, unlike the typical loss-of-function mechanism seen in the recessive disease.

Research and therapeutic approaches: Currently, there are no approved treatments or cures for RDH12-associated retinal dystrophy. Management is primarily supportive, focusing on maximizing remaining vision through low-vision aids, educational support, and regular monitoring of retinal health. Because the disease involves the accumulation of toxic byproducts and oxidative stress, some theoretical approaches have considered antioxidants, but none have proven clinically effective to halt disease progression. However, significant progress is being made in the pipeline for targeted therapies, particularly gene therapy. Since the most common and severe forms of RDH12 retinopathy are caused by loss-of-function mutations, gene augmentation therapy is a highly promising approach. Opus Genetics, in partnership with the Global RDH12 Alliance, is advancing OPGx-RDH12, an adeno-associated virus (AAV) vector-based gene therapy designed to deliver a functional copy of the RDH12 gene directly to the photoreceptors. This therapy has shown promising preclinical data in animal models, demonstrating the ability to restore enzyme function and protect photoreceptors. Preparations for clinical trials are underway, bringing hope for a targeted treatment similar to Luxturna (which is approved for RPE65-associated LCA).

Diagnostic testing: Mutations in the RDH12 gene are typically detected through comprehensive genetic testing approaches. Multi-gene panel testing for inherited retinal diseases (IRDs) or Leber Congenital Amaurosis (LCA) is commonly used, as it simultaneously sequences multiple genes known to cause similar phenotypes. If panel testing is inconclusive, whole exome sequencing (WES) or whole genome sequencing (WGS) may be employed to identify rare or novel variants. Clinical evaluation, including fundus autofluorescence (FAF) and optical coherence tomography (OCT), can reveal characteristic signs like petal-shaped macular atrophy and peripapillary sparing, which can help guide genetic testing toward RDH12. Genetic counseling is crucial for affected individuals and their families. Since RDH12-associated retinopathy is most commonly inherited in an autosomal recessive manner, parents of an affected child are typically obligate carriers, and there is a 25% chance of recurrence in subsequent pregnancies. However, because autosomal dominant inheritance has also been reported for certain mutations, accurate identification of the specific variant is essential for determining the correct inheritance pattern and providing accurate recurrence risks. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family are known.

Animal models: The most common animal model used to study RDH12 is the Rdh12 knockout (KO) mouse. Interestingly, Rdh12-/- mice exhibit a relatively mild phenotype compared to human patients. They show grossly normal retinal histology up to 10 months of age and have sufficient amounts of 11-cis retinal. However, their photoreceptors are significantly more susceptible to light-induced apoptosis than those of wild-type mice. This suggests that the primary disease mechanism is not a simple disruption of the visual cycle, but rather an increased cellular sensitivity to light-induced oxidative injury and the accumulation of toxic byproducts like 4-hydroxynonenal (4-HNE). Zebrafish models are also being developed and utilized because they possess a cone-rich retina, which is highly relevant for studying inherited retinal dystrophies (IRDs) that affect macular and cone function. These models help researchers understand the developmental and functional roles of RDH12 in a system that closely mimics the human macula, providing further insights into the pathophysiology of RDH12-associated retinopathies.

Population genetics: The carrier frequency for RDH12 mutations varies significantly by population. In the general population, it is a rare cause of inherited retinal disease, accounting for roughly 3.5% to 10.5% of all early-onset severe retinal dystrophy (EOSRD) and Leber Congenital Amaurosis (LCA) cases. However, it has a higher prevalence in certain populations. For example, RDH12 mutations are more frequently observed in East Asian populations. Additionally, specific founder mutations have been identified; the p.Ala126Val variant has a notable carrier frequency of approximately 0.62% in the Israeli population. Overall, the genetic prevalence of autosomal recessive inherited retinal diseases is estimated at about 1 in 1,380 individuals, with RDH12 contributing a specific fraction to this global burden.

Selected references: 1. Daich Varela M, et al. RDH12 retinopathy: clinical features, biology, genetics and future directions. Ophthalmic Genet, 2022. PMID: 35491887 2. Scott HA, et al. Expanding the phenotypic spectrum in RDH12-associated retinal disease. Cold Spring Harb Mol Case Stud, 2020. PMID: 32014858 3. Kurth I, et al. Targeted Disruption of the Murine Retinal Dehydrogenase 12 (Rdh12) Gene. Mol Cell Biol, 2006. PMID: 17178824 4. Fingert JH, et al. Association of a Novel Mutation in the Retinol Dehydrogenase 12 (RDH12) Gene With Autosomal Dominant Retinitis Pigmentosa. Arch Ophthalmol, 2008. PMID: 18695104 5. Hanany M, et al. Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases. Proc Natl Acad Sci U S A, 2020. PMID: 31964843 6. Thompson DA, et al. RDH12 mutations in Leber congenital amaurosis. Hum Mol Genet, 2005. PMID: 16204285